Le Lézard
Classified in: Health
Subject: CCA

Sisram Medical to Report FY2023 Financial Results on March 20 and Hold a Conference Call on March 21


Sisram FY2023 earnings conference call to be held on March 21, at 8:00 a.m. Eastern Time

HONG KONG, March 14, 2024 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness group, featuring a distinguished synergistic ecosystem of business building blocks and consumer-focused branding, including Energy Based Devices, Injectables, Aesthetic and Digital Dentistry, Personal Care, and more, today announced that it expects to release its annual results for FY2023, ended December 31, on Wednesday, March 20, 2024.

Sisram's management team will host a conference call to discuss the financial results on Thursday, March 21, 2024, at 8:00 a.m. Eastern Time.

Speakers will include: Mr. Liu Yi, Sisram's Chairman, Mr. Lior Dayan, Sisram's Chief Executive Officer, Mr. Doron Yannai, Alma's CFO, and Ms. Qianli Fang, Sisram's VP of IR and Secretary of the Board.  Following the prepared remarks, management will be available for a question-and-answer session.

Please register in advance for the webinar using the link below: https://us02web.zoom.us/webinar/register/WN_jTdOqJTtQL6-JLKS6vsTvQ

After registering, you will receive a confirmation email with instructions for joining the webinar.

The conference call will begin at:
8:00 a.m. Eastern Time
5:00 a.m. Pacific Time
3:00 p.m. Israel Time

A replay will also be available on Sisram Medical's  IR Events & Presentations page.

About Sisram Medical Ltd

Sisram Medical Ltd (1696.HK) is a global consumer wellness group, featuring a first-of-its-kind synergistic ecosystem of business building blocks and consumer-focused branding, ranging from Energy Based Devices, Injectables, Aesthetic and Digital Dentistry, Personal Care and more. The company is majority-owned by Fosun Pharma, one of China's leading healthcare groups. Sisram Medical went public on the Main Board of the Hong Kong Exchange in September 2017.

Sisram Medical ? Enhancing Quality of Life
http://www.sisram-medical.com  

SOURCE Sisram Medical Ltd


These press releases may also interest you

at 08:35
Teva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
Teva Pharmaceutical Industries Ltd. today published its 2023 Healthy Future Report, sharing its actions to promote healthy people, a healthy planet and a healthy business. The report unveils new targets to achieve net zero emissions across Teva's...

at 08:35
Nvelop Therapeutics Announces Members of Its Scientific Advisory Board
Nvelop Therapeutics, a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today announced the members of its scientific advisory board, bringing together a world-class group of experts...

at 08:34
Pill Puncher Announces New White Labeling Partnerships to Revolutionize Medication Management
Pill Puncher is thrilled to announce the launch of new white labeling partnerships, bringing a customizable approach to medication management. This initiative allows healthcare facilities, pharmaceutical companies, and medical equipment providers to...

at 08:34
Highly Positive, Resilient Employees Less Afraid of AI, Unthreatened About Job Security, and More Likely to Experience Productivity, meQ's AI Study Finds
The implications of Generative AI technology on employees are greatly dependent on their problem-solving skills and how resilient and positive they are, according to the new meQuilibrium (meQ) Workforce Well-being study of 5,989 employed adults...

at 08:30
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset "EL-22" for The Treatment of Obesity
Preclinical results of EL-22 from a 2022 study demonstrated physiological (serum creatine kinase level), physical (body weight change), and functional (rotarod test) improvements in the dystrophic features of mdx mice, a mouse model of Duchenne...

at 08:30
Petauritm Further Expands with Accomplished Evidence and Strategy Executives
Petauri, a leading purpose-built pharmaceutical services platform, announced today the addition of Nicole Lodowski and Bob Nordyke to lead a team dedicated to evidence generation and value strategy across the product lifecycle, from early pipeline...

More news about Health...


News published on and distributed by: